Glaxosmithkline Pharmaceuticals Ltd

Glaxosmithkline Pharmaceuticals Ltd

Next 500 2024
+ 13 More
+ 13 More
OVERVIEW
FINANCIALS

About

GlaxoSmithKline Pharmaceuticals is a subsidiary of the GSK Group in India. Its objective is to get ahead of disease with the help of science, talent, and technology and touch the lives of 2.5 billion people in the next 10 years. After its demerger with Haleon, a consumer healthcare business, GlaxoSmithKline Pharmaceuticals has become a fully focused biopharma company. Its R&D team focuses on the immune system, human genetics, and advanced technologies, primarily in the domain of 4 therapeutic areas: infectious diseases, HIV, oncology, and immunology. GSK’s offerings have been divided into 3 verticals, namely general medicines, vaccines, and specialty medicines. While general medicines cover anti-infectives, pain, dermatology, and vitamins, specialty medicines are targeted at respiratory diseases and HIV. GSK has 60+ vaccines in the pipeline but currently markets 10 for infants, adolescents, and adults.

Incorporation Year: 1924
Headquarters: Mumbai
Top Management: Bhushan Akshikar/MNC
Industry: Pharma

Featured In Fortune India Ranking

Fortune 500 India
#339(2022)
#353(2021)
#304(2020)
#369(2019)
#374(2018)
#354(2017)
#337(2016)
#349(2015)
#339(2014)
#331(2013)
#332(2012)
#319(2011)
#287(2010)
#339(2022)#353(2021)#304(2020)#369(2019)#374(2018)#354(2017)#337(2016)#349(2015)#339(2014)#331(2013)#332(2012)#319(2011)#287(2010)
Ranking Trend Fortune 500 India
#24(2024)

Financial Data 2024

Revenue
3,660
(INR Cr)
Net Operating Income
3,454
(INR Cr)
Assets
2,044
(INR Cr)
Profit
590
(INR Cr)
Net Worth
1,778
(INR Cr)

Financial Data

RevenueNet Operating IncomeProfitAssetsNet Worth
PARAMETERS2024202320222021202020192018201720162015201320122011201020092008
Revenue
(INR Cr)
3660
11.0%
3297
-29.6%
4685
47.3%
3182
-18.1%
3886
19.4%
3254
8.4%
3002
1.9%
2946
-5.6%
3122
-11.0%
3509
24.5%
2818
1.7%
2771
5.9%
2616
13.6%
2302
10.7%
2079
3.4%
2011
-
Net Operating Income
(INR Cr)
3454
6.21%
3252
-0.80%
3278
12.05%
2926
-9.27%
3224
3.08%
3128
8.94%
2871
-1.27%
2908
2.49%
2838
-14.12%
3305
28.95%
2563
-3.17%
2647
9.62%
2414
12.24%
2151
12.63%
1910
12.41%
1699
6.04%
Profit
(INR Cr)
590
-3.4%
611
-64.0%
1695
373.2%
358
284.3%
93
-79.1%
445
27.0%
351
4.1%
337
-10.5%
376
-21.1%
476
-1.1%
482
-14.3%
562
31.1%
429
-23.5%
561
10.4%
508
-14.1%
591
-
Assets
(INR Cr)
2044
1.6%
2012
-31.7%
2947
66.1%
1774
-16.0%
2111
-14.1%
2457
4.7%
2348
2.8%
2284
-7.8%
2476
17.4%
2110
-5.9%
2241
-0.5%
2252
3.8%
2170
10.9%
1957
9.2%
1792
13.3%
1581
-
Net Worth
(INR Cr)
1778
2.1%
1741
-34.6%
2663
80.1%
1478
-18.8%
1821
-14.9%
2140
4.0%
2057
2.5%
2007
-8.1%
2183
19.4%
1829
-8.1%
1990
-0.9%
2007
3.7%
1936
-0.8%
1952
9.3%
1786
13.4%
1576
14.1%
Employee Cost
(INR Cr)
624
4.9%
595
-2.5%
610
-1.0%
616
-2.0%
629
17.0%
537
2.6%
523
8.4%
483
8.9%
443
-10.1%
493
36.2%
362
-8.0%
394
36.9%
287
22.6%
235
15.0%
204
21.2%
168
-
Interest Cost
(INR Cr)
2224610000000101
Cash & Bank Balance
(INR Cr)
10631156248511581083117112969001392191120422067201420031734957
Total Debt
(INR Cr)
19162035011223455556

Key Financial Ratios

Profit As % Of RevenuesRONW %Interest Cost to EBITDA %ROCE %Debt to Equity Ratio
PARAMETERS2024202320222021202020192018201720162015201320122011201020092008
Profit As % Of Revenues 16.1%18.5%36.2%11.3%2.4%13.7%11.7%11.4%12.1%13.6%17.1%20.3%16.4%24.4%24.4%29.4%
Profit As % Of Assets 28.9%30.4%57.5%20.2%4.4%18.1%14.9%14.8%15.2%22.6%21.5%25.0%19.8%28.7%28.4%37.4%
Profit As % Of Networth 33.2%35.1%63.6%24.2%5.1%20.8%17.1%16.8%17.2%26.1%24.2%28.0%22.1%28.7%28.4%37.5%
Interest Cost to EBITDA % 0.2%0.2%0.3%0.9%-0.1%0.0%0.1%0.1%0.1%0.1%-0.1%0.1%0.1%0.1%
Debt to Equity Ratio 0.010.010.010.020.000.000.000.000.000.000.000.000.000.000.000.00
RONW 37.3%27.7%81.3%28.9%10.0%21.2%17.3%16.1%18.8%20.0%24.1%33.3%30.2%30.0%30.2%34.1%
ROCE 45.0%33.9%32.6%32.4%28.5%28.4%23.3%21.5%25.2%27.8%31.7%44.4%45.0%45.1%46.0%47.3%